These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25704399)

  • 1. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox.
    Llona-Minguez S; Ghassemian A; Helleday T
    Prog Lipid Res; 2015 Apr; 58():51-75. PubMed ID: 25704399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.
    Meduri B; Pujar GV; Durai Ananda Kumar T; Akshatha HS; Sethu AK; Singh M; Kanagarla A; Mathew B
    Eur J Med Chem; 2021 Oct; 222():113574. PubMed ID: 34126459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?
    Balijepalli P; Sitton CC; Meier KE
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.
    Willier S; Butt E; Grunewald TG
    Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA
    Taniguchi R; Inoue A; Sayama M; Uwamizu A; Yamashita K; Hirata K; Yoshida M; Tanaka Y; Kato HE; Nakada-Nakura Y; Otani Y; Nishizawa T; Doi T; Ohwada T; Ishitani R; Aoki J; Nureki O
    Nature; 2017 Aug; 548(7667):356-360. PubMed ID: 28792932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of lysophosphatidic acid (LPA) in skeletal biology.
    Blackburn J; Mansell JP
    Bone; 2012 Mar; 50(3):756-62. PubMed ID: 22193551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse effects of LPA receptors on cell motile activities of cancer cells.
    Tsujiuchi T; Hirane M; Dong Y; Fukushima N
    J Recept Signal Transduct Res; 2014 Jun; 34(3):149-53. PubMed ID: 24460191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid receptors in cancer pathobiology.
    Tsujiuchi T; Araki M; Hirane M; Dong Y; Fukushima N
    Histol Histopathol; 2014 Mar; 29(3):313-21. PubMed ID: 24194373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
    Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
    Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease.
    Zhou Y; Little PJ; Ta HT; Xu S; Kamato D
    Pharmacol Ther; 2019 Dec; 204():107404. PubMed ID: 31472182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
    Durgam GG; Tsukahara R; Makarova N; Walker MD; Fujiwara Y; Pigg KR; Baker DL; Sardar VM; Parrill AL; Tigyi G; Miller DD
    Bioorg Med Chem Lett; 2006 Feb; 16(3):633-40. PubMed ID: 16263282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs.
    Liliom K; Tsukahara T; Tsukahara R; Zelman-Femiak M; Swiezewska E; Tigyi G
    Biochim Biophys Acta; 2006 Dec; 1761(12):1506-14. PubMed ID: 17092771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.
    Lin ME; Herr DR; Chun J
    Prostaglandins Other Lipid Mediat; 2010 Apr; 91(3-4):130-8. PubMed ID: 20331961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
    Swaney JS; Chapman C; Correa LD; Stebbins KJ; Broadhead AR; Bain G; Santini AM; Darlington J; King CD; Baccei CS; Lee C; Parr TA; Roppe JR; Seiders TJ; Ziff J; Prasit P; Hutchinson JH; Evans JF; Lorrain DS
    J Pharmacol Exp Ther; 2011 Mar; 336(3):693-700. PubMed ID: 21159750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid, human osteoblast formation, maturation and the role of 1α,25-Dihydroxyvitamin D3 (calcitriol).
    Mansell JP; Blackburn J
    Biochim Biophys Acta; 2013 Jan; 1831(1):105-8. PubMed ID: 22561288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
    Lin YH; Lin YC; Chen CC
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous lysophosphatidic acid (LPA
    Sattikar A; Dowling MR; Rosethorne EM
    Br J Pharmacol; 2017 Feb; 174(3):227-237. PubMed ID: 27864940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
    Velasco M; O'Sullivan C; Sheridan GK
    Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Druggable Lysophospholipid Signaling Pathways.
    Yanagida K; Valentine WJ
    Adv Exp Med Biol; 2020; 1274():137-176. PubMed ID: 32894510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.